Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society

Erik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L. Aisner, Mary Beth Beasley, Alain C. Borczuk, Philip T. Cagle, Vera Luiza Capelozzi, Wendy Cooper, Lida P. Hariri, Izidor Kern, Sylvie Lantuejoul, Ross Miller, Mari Mino-Kenudson, Teodora Radonic, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Prudence Russell, Frank SchneiderLynette M. Sholl, Ming Sound Tsao, Marina Vivero, Yasushi Yatabe

Research output: Contribution to journalReview articleAcademicpeer-review

65 Citations (Scopus)


The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.
Original languageEnglish
Pages (from-to)408-419
JournalArchives of Pathology & Laboratory Medicine
Issue number3
Publication statusPublished - 2018

Cite this